STOK (Stoke Therapeutics) COGS-to-Revenue : 0.00 (As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Stoke Therapeutics COGS-to-Revenue?

Stoke Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2025 was $0.0 Mil. Its Revenue for the three months ended in Mar. 2025 was $158.6 Mil.

Stoke Therapeutics's COGS to Revenue for the three months ended in Mar. 2025 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Stoke Therapeutics's Gross Margin % for the three months ended in Mar. 2025 was N/A%.

Stoke Therapeutics COGS-to-Revenue Historical Data

The historical data trend for Stoke Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stoke Therapeutics COGS-to-Revenue Chart

Stoke Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

Stoke Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Stoke Therapeutics COGS-to-Revenue Calculation

Stoke Therapeutics's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	36.555
	=	0.00

Stoke Therapeutics's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	158.569
	=	0.00

Stoke Therapeutics (NAS:STOK) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Stoke Therapeutics's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 158.569
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Stoke Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Stoke Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Stoke Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stoke Therapeutics Inc (NAS:STOK) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

0GT:Germany

Address

45 Wiggins Avenue, Bedford, MA, USA, 01730

Website

https://www.stoketherapeutics.com

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Executives

Barry Ticho	officer: Chief Medical Officer	C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Jonathan Allan	officer: General Counsel & Corp Sec	C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730
Kaye Edward M. Md	director, officer: CEO	3450 MONTE VILLA PARKWAY, BOTHELL WA 98011
Skorpios Trust	10 percent owner	195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Huw M. Nash	officer: COO & CBO	C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Stephen J Tulipano	officer: CFO	C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Ian F Smith	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Atp Life Science Ventures, L.p.	10 percent owner	230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169
Atp Iii Gp, Ltd.	10 percent owner	230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169
Montrago Trustees Ltd	10 percent owner	195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Blue Horizon Enterprise Ltd	10 percent owner	3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Ezbon International Ltd	10 percent owner	3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Gene Liau	officer: EVP Research & Preclinical Dev	C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Arthur A Levin	director	1896 RUTHERFORD ROAD, CARLSBAD CA 92008
Arthur Tzianabos	director	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730